Swedish IT and medical technology company Sectra has enhanced its product offering within digital radiology through the acquisition of Pronosco A/S, announced Feb. 15. The Copenhagen-based company develops
Swedish IT and medical technology company Sectra has enhanced its product offering within digital radiology through the acquisition of Pronosco A/S, announced Feb. 15. The Copenhagen-based company develops and markets software for diagnosing and monitoring osteoporosis. As part of an agreement implemented in November, Sectra has been integrating Pronosco's software tools with Sectra's system for digital radiography. These tools allow doctors to diagnose and monitor the development of osteoporosis, based on estimates of bone mineral density and the structure of bone derived from a radiograph of the patient's hand. The application will be available as an optional tool on Sectra's workstations.
On Feb. 26, Sectra described the signing of a cooperation agreement with International Medical Multimedia (IMM), a software development company based in the U.K. IMM develops and markets AiMS, image management software that enables radiologists to create and customize image archives for clinical reference, teaching, and presentation purposes. The agreement will allow Sectra to integrate AiMS into its digital radiology workstation.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.